Logo

Publikacije (205)

Nazad
A. Fendler, S. Shepherd, L. Au, Mary Y. Wu, R. Harvey, A. Schmitt, Z. Tippu, B. Shum et al.

Robert Wiesheu, S. Edwards, A. Hedley, K. Kirschner, M. Tosolini, M. Silva, A. Kilbey, Crispin J. Miller et al.

Robert Wiesheu, Sarah C. Edwards, Ann Hedley, Kristina Kirschner, Marie Tosolini, Marcelo Fares da Silva, Anna Kilbey, Crispin Miller, Vasileios Bekiaris, Jean-Jacques Fournier and Seth B. Coffelt Institute of Cancer Sciences, University of Glasgow, UK; Cancer Research UK Beatson Institute, Glasgow, UK; GammaDelta Therapeutics Limited, London, UK; Cancer Research Centre of Toulouse, University of Toulouse, France; Technical University of Denmark, Kongens Lyngby, Denmark

A. Fendler, S. Shepherd, L. Au, K. Wilkinson, Mary Y. Wu, A. Schmitt, Z. Tippu, Sheima Farag et al.

Not all patients with cancer, in particular those with hematogic malignancies, develop functional immunity against SARS-CoV-2 variants of concern (VOC) following COVID-19 vaccines. Durability of vaccine-induced immunity after two doses and the impact of a third dose were evaluated in CAPTURE (NCT03226886), a longitudinal prospective cohort study of vaccine responses in patients with cancer. In evaluating 316 patients, at a median of 111 days following two doses of either BNT16b2 or ChadOX, we observed a time-dependant decline in neutralising antibody titres (NAbT) in a proportion of patients, where NAbTs became undetectable against Delta and Beta in 17% and 15% of patients, respectively. Vaccine-induced T cell responses declined in 44% of patients. Patients with breakthrough infections following two vaccines doses were characterised by absent/low NAbT to Delta prior to infection. Administration of the third vaccine dose boosted NAb responses against VOC in the majority of patients with cancer, especially those with solid cancer. In patients with hematologic malignancies who had undetectable NAbT against Delta after two vaccine doses, 54% did not develop NAb against both Beta and Delta following the third dose. Third vaccine dose boosted T cell responses were boosted in patients with both solid and hematologic malignancies. These results provide critical information on vaccine responses in patients with cancer, especially against VOCs and support widespread access to a third COVID-19 vaccination in this patient group.

A. Fendler, S. Shepherd, L. Au, K. Wilkinson, Mary Y. Wu, A. Schmitt, Z. Tippu, Sheima Farag et al.

S. Turajlic, M. Jamal-Hanjani, A. Furness, R. Plummer, J. Cave, F. Thistlethwaite, Emma Leire, J. Middleton et al.

Ex-vivo expanded tumour infiltrating lymphocytes (TIL) show promise in delivering durable responses among several solid tumour indications. However, characterising, quantifying and tracking the active component of TIL therapy remains challenging as the expansion process does not distinguish between tumour reactive and bystander T-cells. Achilles Therapeutics has developed ATL001, a patient-specific TIL-based product, manufactured using the VELOS™ process that specifically targets clonal neoantigens present in all tumour cells within a patient. Two Phase I/IIa clinical trials of ATL001 are ongoing in patients with advanced Non-Small Cell Lung Cancer, CHIRON (NCT04032847), and metastatic or recurrent melanoma, THETIS (NCT03997474). Extensive product characterisation and immune-monitoring are performed through Achilles’ manufacturing and translational science programme. This enables precise quantification and characterisation of the active component of this therapy – Clonal Neoantigen T cells (cNeT) – during manufacture and following patient administration, offering unique insight into the mechanism of action of ATL001 and aiding the development of next generation processes.ATL001 was manufactured using procured tumour and matched whole blood from 8 patients enrolled in the THETIS (n=5) and CHIRON (n=3) clinical trials. Following administration of ATL001, peripheral blood samples were collected up to week 6. The active component of the product was detected via re-stimulation with clonal neoantigen peptide pools and evaluation of IFN-γ and/or TNF-α production. Deconvolution of individual reactivities was achieved via ELISPOT assays. Immune reconstitution was evaluated by flow cytometry. cNeT expansion was evaluated by restimulation of isolated PBMCs with peptide pools and individual peptide reactivities (ELISPOT).The median age was 57 (range 30 – 71) and 6/8 patients were male. The median number of previous lines of systemic anti-cancer treatment at the time of ATL001 dosing was 2.5 (range 1 – 5). Proportion of cNeT in manufactured products ranged from 0.20% - 77.43% (mean 26.78%) and unique single peptide reactivities were observed in 7 of 8 products (range 0 – 28, mean 8.6). Post-dosing, cNeTs were detected in 5/8 patients and cNeT expansion was observed in 3/5 patients.These data underscore our ability to sensitively detect, quantify and track the patient-specific cNeT component of ATL001 – during manufacture and post dosing. As the dataset matures, these metrics of detection and expansion will be correlated with product, clinical and genomic characteristics to determine variables associated with peripheral cNeT dynamics and clinical response.NCT04032847, NCT03997474The first 8 patients described have all been located within the UK and both trials (CHIRON and THETIS) have been approved by the UK MHRA (among other international bodies, e.g FDA). Additionally, these trials have been approved by local ethics boards at active sites within the UK. Patient‘s are fully informed by provided materials and investigators prior to consenting to enrol into either ATL001 trial.

L. Au, E. Hatipoglu, M. Robert de Massy, K. Litchfield, G. Beattie, A. Rowan, Desiree Schnidrig, R. Thompson et al.

S. Shepherd, A. Fendler, L. Au, F. Byrne, K. Wilkinson, M. Wu, A. Schmitt, N. Joharatnam-Hogan et al.

Nema pronađenih rezultata, molimo da izmjenite uslove pretrage i pokušate ponovo!

Pretplatite se na novosti o BH Akademskom Imeniku

Ova stranica koristi kolačiće da bi vam pružila najbolje iskustvo

Saznaj više